1. Much better results were obtained with such chelating agents as HEHA (1,4,7,10,13,16-hexaazacyclohexadecane-N,N′,N′′,N′′′,N′′′′,N′′′′′-hexaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) coupled to trastuzumab, a monoclonal antibody that interferes with the HER2/neu receptor.

하지만, 또 다른 킬레이트 물질인 HEHA(1,4,7,10,13,16-hexaazacyclohexadecane-N,N`,N``,N```,N````,N`````-hexaacetic acid) 혹은 단일 클론인 트라스트주맙과 섞인 DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)를 이용했을 땐 훨씬 더 좋은 결과가 나왔다.